🇺🇸 PEG-interferon alfa-2b in United States

84 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 84

Most-reported reactions

1. Anaemia — 13 reports (15.48%)
2. Granulomatous Liver Disease — 9 reports (10.71%)
3. Nausea — 9 reports (10.71%)
4. Pyrexia — 9 reports (10.71%)
5. Asthenia — 8 reports (9.52%)
6. Retinopathy — 8 reports (9.52%)
7. Thrombocytopenia — 8 reports (9.52%)
8. Vomiting — 8 reports (9.52%)
9. Aplasia Pure Red Cell — 6 reports (7.14%)
10. Confusional State — 6 reports (7.14%)

Source database →

Frequently asked questions

Is PEG-interferon alfa-2b approved in United States?

PEG-interferon alfa-2b does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for PEG-interferon alfa-2b in United States?

Barbara Ann Karmanos Cancer Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.